Important April 7, 2025 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, in the Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ('MDD') to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.
THE LEAD PLAINTIFF PROCESS:
Neumora investors may, no later than April 7, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Axon (NASDAQ:AXON) Reports Upbeat Q2, Full-Year Outlook Slightly Exceeds Expectations
Self defense company AXON (NASDAQ:AXON) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 32.8% year on year to $668.5 million. The company's full-year revenue guidance of $2.69 billion at the midpoint came in 1.2% above analysts' estimates. Its non-GAAP profit of $2.12 per share was 45% above analysts' consensus estimates. Is now the time to buy Axon? Find out in our full research report. Axon (AXON) Q2 CY2025 Highlights: Revenue: $668.5 million vs analyst estimates of $641 million (32.8% year-on-year growth, 4.3% beat) Adjusted EPS: $2.12 vs analyst estimates of $1.46 (45% beat) Adjusted EBITDA: $171.6 million vs analyst estimates of $160.7 million (25.7% margin, 6.8% beat) The company lifted its revenue guidance for the full year to $2.69 billion at the midpoint from $2.65 billion, a 1.5% increase EBITDA guidance for the full year is $675 million at the midpoint, in line with analyst expectations Operating Margin: -0.2%, down from 6.7% in the same quarter last year Free Cash Flow was -$114.7 million, down from $75.3 million in the same quarter last year Market Capitalization: $57.8 billion Company Overview Providing body cameras and tasers for first responders, AXON (NASDAQ:AXON) develops technology solutions and weapons products for military, law enforcement, and civilians. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, Axon's 32.3% annualized revenue growth over the last five years was incredible. Its growth surpassed the average industrials company and shows its offerings resonate with customers, a great starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. Axon's annualized revenue growth of 32.4% over the last two years aligns with its five-year trend, suggesting its demand was predictably strong. This quarter, Axon reported wonderful year-on-year revenue growth of 32.8%, and its $668.5 million of revenue exceeded Wall Street's estimates by 4.3%. Looking ahead, sell-side analysts expect revenue to grow 23.2% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is healthy and indicates the market is baking in success for its products and services. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. Axon was profitable over the last five years but held back by its large cost base. Its average operating margin of 1.8% was weak for an industrials business. On the plus side, Axon's operating margin rose by 17.7 percentage points over the last five years, as its sales growth gave it immense operating leverage. This quarter, Axon's breakeven margin was down 6.9 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Axon's EPS grew at an astounding 45.6% compounded annual growth rate over the last five years, higher than its 32.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into Axon's quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Axon's operating margin declined this quarter but expanded by 17.7 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don't tell us as much about a company's fundamentals. Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business. For Axon, its two-year annual EPS growth of 46.5% is similar to its five-year trend, implying strong and stable earnings power. In Q2, Axon reported adjusted EPS at $2.12, up from $1.20 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Axon's full-year EPS of $7.06 to shrink by 6.1%. Key Takeaways from Axon's Q2 Results We were impressed that Axon beat analysts' revenue and EBITDA expectations this quarter. Looking ahead, full-year revenue guidance was raised, showing a strong demand environment. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 4.1% to $773 immediately following the results. Sure, Axon had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
an hour ago
- Yahoo
Palantir Tops Q2, Raises Full-Year Forecast
Palantir (NASDAQ:PLTR) smashes Q2 forecasts with $0.16 Non-GAAP EPS and $1 billion revenue, then lifts full-year targets. The company delivered EPS of $0.16, beating by $0.02, and revenue jumped 47.5% to $1 billion, topping consensus by $60.53 million. Management projected Q3 revenue of $1.083 billion$1.087 billion versus $981.99 million expected and boosted full-year sales guidance to $4.142 billion$4.150 billion from a $3.90 billion consensus. Adjusted operating income is now seen at $1.912 billion$1.920 billion, while free cash flow is guided to $1.8 billion$2.0 billion. Warning! GuruFocus has detected 7 Warning Sign with MSFT. This beat-and-raise follows several quarters of accelerating growth, driven by strong demand across government and commercial segments. The higher guidance signals confidence in pipeline momentum and the company's ability to convert contracts into cash. It also underlines Palantir's push to sustain its blistering growth profile in an industry where peers often stumble on scale. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
MercadoLibre (NASDAQ:MELI) Beats Q2 Sales Targets But Stock Drops
Latin American e-commerce and fintech company MercadoLibre (NASDAQ:MELI) announced better-than-expected revenue in Q2 CY2025, with sales up 33.8% year on year to $6.79 billion. Its GAAP profit of $10.31 per share was 13.3% below analysts' consensus estimates. Is now the time to buy MercadoLibre? Find out in our full research report. MercadoLibre (MELI) Q2 CY2025 Highlights: Revenue: $6.79 billion vs analyst estimates of $6.54 billion (33.8% year-on-year growth, 3.9% beat) EPS (GAAP): $10.31 vs analyst expectations of $11.89 (13.3% miss) Adjusted EBITDA: $1.02 billion vs analyst estimates of $1.06 billion (15.1% margin, 3.2% miss) "This compression [in margin] was primarily driven growth investments..., and marketing spend also increased to support our free shipping and Mercado Pago campaigns. We are confident these are the right investments to make for the benefit of our users and our ecosystem" Operating Margin: 12.2%, down from 14.3% in the same quarter last year Free Cash Flow Margin: 38.7%, up from 12.8% in the previous quarter Unique Active Buyers: 71 million, up 14.4 million year on year Market Capitalization: $121.5 billion Company Overview Originally started as an online auction platform, MercadoLibre (NASDAQ:MELI) is a one-stop e-commerce marketplace and fintech platform in Latin America. Revenue Growth A company's long-term sales performance can indicate its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, MercadoLibre's sales grew at an incredible 39.7% compounded annual growth rate over the last three years. Its growth surpassed the average consumer internet company and shows its offerings resonate with customers, a great starting point for our analysis. This quarter, MercadoLibre reported wonderful year-on-year revenue growth of 33.8%, and its $6.79 billion of revenue exceeded Wall Street's estimates by 3.9%. Looking ahead, sell-side analysts expect revenue to grow 27.8% over the next 12 months, a deceleration versus the last three years. Still, this projection is eye-popping given its scale and implies the market is baking in success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Unique Active Buyers User Growth As an online marketplace, MercadoLibre generates revenue growth by increasing both the number of users on its platform and the average order size in dollars. Over the last two years, MercadoLibre's unique active buyers, a key performance metric for the company, increased by 20.8% annually to 71 million in the latest quarter. This growth rate is among the fastest of any consumer internet business and indicates its offerings have significant traction. In Q2, MercadoLibre added 14.4 million unique active buyers, leading to 25.4% year-on-year growth. The quarterly print was higher than its two-year result, suggesting its new initiatives are accelerating user growth. Revenue Per User Average revenue per user (ARPU) is a critical metric to track because it measures how much the company earns in transaction fees from each user. ARPU also gives us unique insights into a user's average order size and MercadoLibre's take rate, or "cut", on each order. MercadoLibre's ARPU growth has been exceptional over the last two years, averaging 15.4%. Its ability to increase monetization while growing its unique active buyers at an impressive rate reflects the strength of its platform, as its users are spending significantly more than last year. This quarter, MercadoLibre's ARPU clocked in at $95.63. It grew by 6.7% year on year, slower than its user growth. Key Takeaways from MercadoLibre's Q2 Results This compression [in margin] was primarily driven growth investments..., and marketing spend also increased to support our free shipping and Mercado Pago campaigns. We are confident these are the right investments to make for the benefit of our users and our ecosystem" Should you buy the stock or not? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
